Literature DB >> 7499782

Analysis of prognostic variables in the prediction of mortality, shunt failure, variceal rebleeding and encephalopathy following the transjugular intrahepatic portosystemic stent-shunt for variceal haemorrhage.

R Jalan1, R A Elton, D N Redhead, N D Finlayson, P C Hayes.   

Abstract

BACKGROUND/AIMS: The aim of this study was to analyse prognostic variables predicting mortality, shunt insufficiency, variceal rebleeding and encephalopathy following transjugular intrahepatic portosystemic stent-shunt for variceal haemorrhage.
METHODS: Sixty-eight patients with cirrhosis who successfully underwent transjugular intrahepatic portosystemic stent-shunt for variceal haemorrhage were studied. Mean age was 54.8 years (s.e. 1.5); 41 were males and 27 were females. Mean Child score was 8.3 (s.e. 0.3). Cirrhosis was alcohol related in 47. The patients have been followed up for a mean of 10.8 (s.e. 1.1) months. The univariate association between 30 prognostic variables and post-treatment encephalopathy was tested by the Chi-squared or Wilcoxon rank-sum tests and multiple logistic regression was used to test the significance of factors adjusted for one another. Cox's proportional hazard regression was used to test the univariate and multivariate significance of the other three outcomes.
RESULTS: Transjugular intrahepatic portosystemic stent-shunt was performed successfully in 89.5% of patients. Twenty-two patients have died and eight have been transplanted. Fourteen patients died within 30 days of transjugular intrahepatic portosystemic stent-shunt and death was predicted independently by hyponatraemia (p < 0.001) and by severe liver disease (Child C, p < 0.001). Eight patients died during follow up and survival in the long term was predicted independently by the presence of encephalopathy (p < 0.001) prior to transjugular intrahepatic portosystemic stent-shunt (p < 0.001). Shunt insufficiency was predicted by an initial portal pressure gradient of greater than 18 mmHg (p < 0.01). None of the variables analysed predicted variceal rebleeding. Encephalopathy following transjugular intrahepatic portosystemic stent-shunt was only predicted indepedently by its presence prior to transjugular intrahepatic portosystemic stent-shunt (p < 0.001).
CONCLUSIONS: The results of this study suggest that patients with severe liver disease and hyponatraemia are liable to die early, and the presence of encephalopathy prior to transjugular intrahepatic portosystemic stent-shunt independently determines long-term survival. Patients in these groups should be considered high risk and worked up for orthotopic liver transplantation early. Shunt function in patients with an initial portal pressure gradient of > 18 mmHg requires close supervision. Encephalopathic patients should have smaller shunts and prophylactic measures to prevent worsening encephalopathy.

Entities:  

Mesh:

Year:  1995        PMID: 7499782     DOI: 10.1016/0168-8278(95)80325-4

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  44 in total

Review 1.  TIPSS 10 years on.

Authors:  R Jalan; H F Lui; D N Redhead; P C Hayes
Journal:  Gut       Date:  2000-04       Impact factor: 23.059

Review 2.  Acute variceal bleeding: general management.

Authors:  D Patch; L Dagher
Journal:  World J Gastroenterol       Date:  2001-08       Impact factor: 5.742

Review 3.  Current status of transjugular intrahepatic portosystemic shunts.

Authors:  N H Patel; N Chalasani; R M Jindal
Journal:  Postgrad Med J       Date:  1998-12       Impact factor: 2.401

4.  New model for end stage liver disease improves prognostic capability after transjugular intrahepatic portosystemic shunt.

Authors:  Jennifer Guy; Ma Somsouk; Stephen Shiboski; Robert Kerlan; John M Inadomi; Scott W Biggins
Journal:  Clin Gastroenterol Hepatol       Date:  2009-06-26       Impact factor: 11.382

5.  Should stent-grafts replace bare stents for primary transjugular intrahepatic portosystemic shunts?

Authors:  Manfred Cejna
Journal:  Semin Intervent Radiol       Date:  2005-12       Impact factor: 1.513

6.  Hepatic encephalopathy: you should only comment on what you have actually measured.

Authors:  Sara Montagnese; Sami Schiff; Angelo Gatta; Oliviero Riggio; Marsha Y Morgan; Piero Amodio
Journal:  J Gastroenterol       Date:  2009-12-10       Impact factor: 7.527

Review 7.  Emergent Transjugular Intrahepatic Portosystemic Shunt Creation in Acute Variceal Bleeding.

Authors:  Mithil B Pandhi; Andrew J Kuei; Andrew J Lipnik; Ron C Gaba
Journal:  Semin Intervent Radiol       Date:  2020-03-04       Impact factor: 1.513

8.  Incidence of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt (TIPS) according to its severity and temporal grading classification.

Authors:  Paolo Fonio; Andrea Discalzi; Marco Calandri; Andrea Doriguzzi Breatta; Laura Bergamasco; Silvia Martini; Antonio Ottobrelli; Dorico Righi; Giovanni Gandini
Journal:  Radiol Med       Date:  2017-05-16       Impact factor: 3.469

9.  Risk factors and prevention of early infection after implantation or revision of transjugular intrahepatic portosystemic shunts: results of a randomized study.

Authors:  P Deibert; S Schwarz; M Olschewski; V Siegerstetter; H E Blum; M Rössle
Journal:  Dig Dis Sci       Date:  1998-08       Impact factor: 3.199

10.  Shunting branch of portal vein and stent position predict survival after transjugular intrahepatic portosystemic shunt.

Authors:  Ming Bai; Chuang-Ye He; Xing-Shun Qi; Zhan-Xin Yin; Jian-Hong Wang; Wen-Gang Guo; Jing Niu; Jie-Lai Xia; Zhuo-Li Zhang; Andrew C Larson; Kai-Chun Wu; Dai-Ming Fan; Guo-Hong Han
Journal:  World J Gastroenterol       Date:  2014-01-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.